TKT and leukemia: The BCR-ABL gene, which results from a reciprocal translocation between chromosomes 9 and 224, encodes a tyrosine kinase (TK) that contributes to the malignant phenotype of Philadelphia-positive (Ph+) leukemia cells and therefore has been an attractive target for leukemia treatment.